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Wen-Hua Chiou* and Yu-Min ChiangAn asymmetric synthesis to the dendrobatid alkaloid ()-epibatidine
has been described, featuring chiral resolution of both optically pure
7-azabicyclo[2.2.1]heptanecarboxylic acid, and subsequent trans-
formations to ()-epibatidine. The methodology provides a ﬂexible
access to various substituted chiral epibatidine analogues.In 1992, Daly and coworkers reported a dendrobatid alkaloid,
epibatidine (1), isolated in trace amounts from the skin of the
Ecuadoran poison frog Epipedobates tricolor.1,2 Epibatidine (1)
has been found to be 200–400 times more potent thanmorphine
as an analgesic, and appeared to act via a non-opioid mecha-
nism since its eﬀects are not blocked by the opiate receptor
antagonist naloxone. In addition, epibatidine (1) is an extremely
potent agonist of the nicotinic acetylcholine receptor.3 Due to its
pharmacological activity, epibatidine (1) has attracted much
attention from synthetic chemists, resulting in abundant
approaches. However, its high toxicity also prevents therapeutic
applications, and has prompted a search for safer analogues
such as epiboxidine (2) (Fig. 1).4
Various strategies have been developed for eﬃcient
syntheses of the molecule, which have been reviewed by Tru-
dell5 and Olivo.6 One of these approaches to synthesize the
unique 7-azabicyclo[2.2.1]heptane framework in epibatidine is
the cycloaddition reaction. N-Protected pyrroles could undergo
Diels–Alder reactions with substituted acetylene or ethylene
derivatives. Transannular SN2 displacement also provides a
practical route to synthesize epibatidine.7 A well-established
arrangement in a 1,4-disubstituted cyclohexyl ring system could
trigger an SN2 reaction to give the 7-azabicyclo[2.2.1]heptanesing University, Taichung, Taiwan, 402,
on.nchu.edu.tw; Fax: +886-4-22862547;
ESI) available: Experimental procedure,
ent for all compounds, and HPLC
14, and crystallographic data of 4a.
I and crystallographic data in CIF or
c4ra00770k
6structure. Direct coupling of the 7-azabicyclo[2.2.1]heptan-2-
one or its derivatives with the aromatic ring is an eﬀective
strategy for syntheses of epibatidine and analogues. Due to the
diversity of the approach, many elegant approaches to synthe-
size 7-azabicyclo[2.2.1]heptane derivatives have been reported,8
including Aza-Prins-Pinacol rearrangement8e and Favorskii
rearrangement of tropinone.9a,b As a part of the project devoted
to asymmetric syntheses of alkaloids and derivatives for phar-
maceutical purposes, here we describe a diﬀerent approach to
synthesize ()-epibatidine (1). This strategy takes advantage of
readily available carboxylic acid 3, and features a practical
preparation of enantiopure acid 3 and construction of the
2-chloropyridine moiety from the carboxylic acid end.
Our approach commences with the preparation of racemic
7-azabicyclo[2.2.1]heptanecarboxylic acid, using Fevig' con-
ditions,9c a modication based on Bai's procedure.9a,b We envi-
sion both optically active 7-azabicyclo[2.2.1]heptane carboxylic
acids 3 are available through covalent bond modication with a
chiral compound to two separable diastereomers, followed by
removal of the chiral auxiliary. Subsequent functionality trans-
formations of the carboxylic acid end eﬀect the formation of the
2-chloropyridine moiety in epibatidine. Such an approach does
not only synthesize the 2-chloropyridine moiety, but also allow
diversity by construction of various bioisosteric rings or other
modication. For example, epiboxidine (2) can be achieved by
an acetoxime addition–cyclization protocol.8g With racemic acid
3 in hand, transformation of ()-3 to separable diastereomers
has been carried out by treating of acid 3 with SOCl2 to the
resulting acid chloride, followed by reaction with various chiral
auxiliaries.Fig. 1 ()-Epibatidine (1) and epiboxidine (2).
This journal is © The Royal Society of Chemistry 2014
Fig. 3 ORTEP drawing of oxazolidinone 4a.
Communication RSC AdvancesWe have utilized L-menthol and L-borenol as the chiral
auxiliary, but both have failed to give separable diastereomeric
adducts. Fortunately, aer racemic acid 3 has been coupled
with (4S)-benzyl-2-oxazolidinone, readily available from
L-phenylalanine, two diastereomeric adducts were easily sepa-
rated by column chromatography, to yield the less polar product
4a in 44% yield and the more polar product 4b in 41% yield,
respectively (Scheme 1). In addition, recrystallization of oxazo-
lidinone 4a within ethyl acetate and hexane provided a crystal
for an X-ray analysis, which conrmed the absolute congura-
tion as (1R,2S,4S)-7-azabicyclo[2.2.1]heptane moiety (Fig. 2).10
The results also disclosed the absolute conguration of the
other diastereomer, amide 4b, as a (1S,2R,4R)-7-azabicyclo
[2.2.1]heptane moiety. Subsequent basic hydrolysis conditions
using H2O2 in THF for the less polar oxazolidinone derivative 4a
proceeded successfully to yield optically pure ()-acid 3 in 98%
yield, while the more polar one 4b gave optically pure (+)-acid 3
in 93% yield (Scheme 1). Chiral HPLC analyses display the
optical purity of ()-acid 3 is more than 99% ee, (tR: 18.4 min for
(+)-3, 26.3 min for ()-3, see ESI†) (Fig. 3).
The next eﬀorts were involved with the construction of the 5-
substituted-2-chloropyridine moiety (Schemes 2 and 3). With
optically pure acid ()-3 in hand, we converted acid 3 to its
homoaldehyde derivative by one-carbon homologation via an enol
ether intermediate.11 Thus, reduction of acid ()-3 with BH3$Me2S
in THF produced alcohol ()-5 in 96% yield with 99% ee. Oxida-
tion of alcohol ()-5 with Dess–Martin periodinane in CH2Cl2
aﬀorded aldehyde (+)-6 in 93% yield. Direct treatment of oxazoli-
dinone 4a with BH3$Me2S in THF, followed by Dess–Martin
oxidation also aﬀorded aldehyde (+)-6 in 86% yield over two steps.
Treatment aldehyde (+)-6 with methoxymethylene yield, prepared
by mixing of methoxymethyltriphenylphosphonium chloride with
NaHMDS, yielded methyl vinyl ether 7 in 88% yield. About 3 : 2Scheme 1 Separation of racemic acid 3 using (4S)-benzyl-2-
oxazolidinone.
Fig. 2 Approaches towards epibatidine.
This journal is © The Royal Society of Chemistry 2014ratio of the trans isomer to cis isomer was observed in 1H-NMR
spectra, i.e. a doublet at 6.27 ppm with coupling constant 12.8 Hz
implied the trans isomer while a doublet at 5.70 ppm with
coupling constant 6.0 Hz implied the cis isomer. Hydrolysis of
vinyl ether 7 in 1 N HCl in THF furnished homoaldehyde ()-8 in
92% yield. To conrm the chiral integrity, homoaldehyde ()-8
was oxidized by Jones reagent to homoacid ()-9. Chiral HPLC
analysis of homoacid ()-9 conrmed the chiral integrity arrived
intact during the processesmentioned above (>99% ee, Scheme 2).
Homoaldehyde ()-8 was treated with pyrrolidine in the
presence of K2CO3 to the corresponding enamine, followed by
reaction with ethyl acrylate, and then hydrolysis in an acidic
media to furnish glutarate semialdehyde 10 in 55% yield. The
yield was improved to 81% yield by Hagiwara's protocol,12 using
TMSNEt2 and ethyl acrylate in reuxing acetonitrile. Glutarate
semialdehyde 10 underwent a double condensation process
with NH4OAc in reuxing benzene to yield dihydropyridone
()-11 in 93% yield with 99% ee. Oxidation with 9 equivalents of
MnO2 in reuxing benzene produced 5-substituted 2-pyridone
(+)-12 in 90% yield. Slow addition of MnO2 during a long period
was crucial for the yield in that addition at once brought about a
yield decrease in this reaction. Treatment of 2-pyridone (+)-12
with POCl3 and in DMF did not only convert the 2-pyridone
group to the 2-chloropyridine group, but also replaced the Cbz
group by a formyl group as formamide 13 in 73% isolated yield.
Since two sets of peaks with almost equal intensity have been
observed in 13C-NMR, the product appeared to be a mixture of
E/Z isomers with equal amount due to the restrict rotation of
the formamide bonding. Exposure of formamide 13 in 5% HCl
in MeOH aﬀorded nal product epibatidine ()-1 in 92% yield
with >99% ee. The specic rotation value of ()-1, [a]25D  6.8 (c:
1.04 CHCl3) was consistent with the reported value, [a]
25
D  6.5Scheme 2 Synthesis of chiral aldehyde ()-8.
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Scheme 3 Syntheses of ()-epibatidine and (+)-methylepibatidine.
RSC Advances Communication(c: 1.00, CHCl3).13 Treatment of formamide 13 with alane
complex, prepared by mixing LiAlH4 and Et3N$HCl,14 produced
N-methyl epibatidine analogue (+)-14 in 76% yield with 99% ee
(Scheme 3).
In conclusion, we have described an eﬃcient preparation of
both enantiomers of 7-azabicyclo[2.2.1]heptane carboxylic acid
3, and a feasible strategy to synthesize a 5-substituted 2-chlor-
opyridine structure from a cycloalkanecarboxylic acid, demon-
strated as the synthesis of ()-epibatidine 1. The methodology
provides exible access to various substituted alkaloids bearing
a 7-azabicyclo[2.2.1]heptane moiety, which may benet the
development of more potent and safer analgesics. Subsequent
extension of this methodology towards other natural products
of interest is currently underway.Acknowledgements
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